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Summary To understand the mechanisms and identify novel approaches to overcoming retinoic acid (RA) resistance in acute promyelocytic
leukaemia (APL), we established the first human RA-resistant APL model in severe combined immunodeficiency (SCID) mice. UF-1 cells, an
RA-resistant APL cell line established in our laboratory. were transplanted into human granulocyte-macrophage colony-stimulating factor
(GM-CSF)-producing SCID (hGMTg SCID) mice and inoculated cells formed subcutaneous tumours in all hGMTg SCID mice, but not in the
non-transgenic control SCID mice. Single-cell suspensions (UF-1/GMTg SCID cells) were similar in morphological, immunological.
cytogenetic and molecular genetic features to parental UF-1 cells. All-trans RA did not change the morphological features of cells or their
expression of CD11b. RA did not alter the growth curve of cells as determined by MTT assay, suggesting that UF-1/GMTg SCID cells are
resistant to RA. These results demonstrate that this is the first RA-resistant APL animal model that may be useful for investigating the biology
of this myeloid leukaemia in vivo. as well as for evaluating novel therapeutic approaches including patients with RA-resistant APL.
Keywords: acute promyelocytic leukaemia; severe combined immunodeficiency mice: human granulocyte-nacrophage colony-stimulating
factor: retinoic acid: drug resistance
All-tranis retinoic acid (RA can induce terminal differentiation of
the leukaemic cells. resulting in complete remission in most
patients wxith acute promrelocxtic leukaemia (APL) (Huang et al.
1988: Kanamaru et al. 1995: Warrell et al. 1991T. Hoxxexer. the
majority of patients became RA resistant x-ith continuous treat-
ment w-ith RA (Warrell et al. 1993). 'Mechanisms and strategies to
oxercome RA resistance in APL are still unclear. and it is a serious
clinical problem for differentiation-inducing therapy. Recently. we
established a noxel APL cell line (tUF-l ) with RA-resistant
features that w-ill be a useful model for studies on the block of
differentiation of the leukaemic cells (Kizak-i et al. 1996a).
Hoxwexer. studies based on the analx-sis of cell lines in -xitro max
not reflect in vivo conditions. Thus. a suitable in xixo model for
human APL is critical for inxestigating mechanisms of RA resis-
tance and to dexelop noxel therapeutic drugs for patients.
Sexere combined immunodeficient (SCID mice haxe been used
as a model for studving the biologx of human disease. Unlike
l-mphoid leukaemic cells. human myeloid leukaemic cells haxe
been difficult to propagate in SCID mice (IUckun et al. 1996). It
has been showxn that cvtokines. and fetal bone and thx mus.
increase the reconstitution capacitv of the human haematopoietic
Received 9 December 1997
Revised 10 March 1998
Accepted 18 March 1998
Correspondence to: M Kizaki. Division of Haematology. Keio University
School of Medicine. 35 Shinanomachi. Shinjuku-ku. Tokyo 160-8582. Japan
s-stem in SCID mice (Lapidod et al. 1994). To address these
problems. >-e haxe established human granulocvte-macrophage
colony-stimulating factor (G.M-CSF)-producing transgenic SCID
(hGMTg SCID) mice (Nlixavakaa et al. 1996). In this report. xxe
demonstrate and characterize the first human RA-resistant APL
model using LTF-I cells and hGNITg SCID mice.
MATEIALS AND METHODS
Cells and chemicals
The RA-resistant APL cell line (UF-1) wxas established in our
laboratorx (Kizaki et al. 1996a). RA-sensitixe HL-60 and N34
cells (the latter a gift from Dr M Lanotte. H6pital St. Louis. Paris.
France) (Lanotte et al. 1991) xxere maintained in RPMI1-1640
medium (Gibco-BRL. Gaitherbur2. MID. USA) containin 15%c
fetal boxine serum (FBS: Hy-clone Laboratories. Logan. UT.
USA). 100 U ml-' penicillin and 100 ig ml-' streptomycin in a
humidified atmosphere wxith 59 carbon dioxide. All-tran2s RA-xas
purchased from Si2ma Chemical Co. (St. Louis. M1O. USA) and
dissolxed in 100%- ethanol to a stock concentration of I mx\. stored
at -20C and protected from light.
Transgenic (Tg) SCID mice producing human GM-CSF
Human GMI-CSF transgenic )hGITg) SCID mice used in this
study xxere newxly produced as described prexiously (Mixak-axa
et al. 1996). Briefl,. equal numbers of pCDSRxhGMI-CSF and
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Figure 1 Histopathology and morphology of subcutaneous tumour in the UF-1-injected SCID mouse. (A and B) Section of subcutaneous tumour in the hGMTg
SCID mouse with diffuse infiltration of leukaemic cells. Tissue was fixed in 10%O forrnalin and embedded in paraffin, and then stained with haematoxylin and
eosin [original magnification x 40 (A) and x 400 (B)]. (C and D) Morphology of parental UF-1 (C) and UF-1/GMTg SCID cells (D). Single-cell suspensions
(UF-1/GMTg SCID cells) were collected and cytospin slides were prepared and stained with Giemsa [original magnification x 1000 (C and D)]
pCDSRcahIL-3 plasmids (provided by Dr Y Takebe. National
Institute ofInfectious Diseases. Tokvo. Japan) (Takebe et al. 1988)
linearized with ApaLI (Takara Shuzo. Tokyo. Japan) were mixed
and microinjected into prenuclear stage embrvos obtained by
crossing BDF1 females with C.B-17-scid or C57B6/J (B6J)-scid
males. A Tg mouse producing hGM-CSF in the sera born of
two founder mice. w-hich carried both pCDSRothGM-CSF and
pCDSRahIL-3 in their genomes. was crossed with B6J-scid to
obtain hGM-CSF producing scidlscid offspring. The mice were
maintained bv back-crossine with B6J-scid under specific
pathogen-free conditions in ourlaboratory. Serum levels ofhuman
GM-CSF w-ere measured using an enzy-me-linked immunosorbent
assay (ELISA) kit (R&D Systems. Minneapolis. MN. USA) in
triplicate according to the manufacturer's instruction.
Inoculation of UF-1 cells into hGMTg SCID mice
UF-l cells (1 x 10- cells) were inoculated either intraperitoneally
(i.p.) or subcutaneously (s.c.) into hGMTg SCID and control B6J
SCID mice. Mice were pretreated with 3 G', of total-body irradia-
tion. a sublethal dose that may enhance acceptance of xenografts
(MivakawAa et al. 1996). Leukaemic cell arowth Awas assessed by
daily measurements of the dimension of subcutaneous nodules.
When the animals showed severe wasting. they w-ere not observed
further and the day of sacrifice w-as recorded to estimate lifespan
according to the UKCCCR guidelines (XXorkman et al. 1988).
Surviving mice were sacrificed at the end of the experiment and
sectioned for microscopic examination of the tumour.
Analysis of leukaemic cells and tissue infiltration
Morphology andhistopathology
A leukaemic tumour nodule was remoxed from SCID mice. cut
into small pieces with a scalpel and then gently ground in a nylon
cell strainer within a tissue culture dish containing, RPMI-1640
medium. Single-cell suspensions (UF-l/GMTgr SCID cells) were
collected and morphologv was evaluated from cytospin slide
preparations with Giemsa stain. To estimate the infiltration of the
leukaemic cells in different organs. tissue sections from mice w-ere
fixed in 10%- formalin and paraffin embedded. and then stained
w-ith haematoxvlin and eosin.
Cytogenetic studies
Chromosomes of UF-l/GMNITg SCID cells were analysed by stan-
dard Giemsa banding techniques as descnrbed previously (Kamada
etal. 1981).
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Table 1 Engraftment of UF-1 cells in hGMTg SCID mice
Serum levels Route of
Mice Sex Age of hGM-CSF inoculation Engraftment Findings
(weeks) (pg m[') (days after inoculation)
hGMTg SCID
1 M 13 6440 sc. + (27) Subcutaneous tumour
2 M 13 >10 000 i.p. + (52) Subcutaneous tumour. ascites.
lntraabdominal tumour
3 F 10.5 6640 sc + (20) Subcutaneous tumour
4 F 10.5 6760 i.p. + (59) Subcutaneous tumour. abscess
B6J SCID
1 M 10.5 - s.c. -
2 M 10.5 - i.p. -
3 F 10.5 - s.c. + (83) Subcutaneous tumour
4 F 10.5 - i.p. - (tumour/total body weight 1.6°o)
Twenty-four hours after 3 Gy of TBI. SCID mice were injected s.c. or i.p. with 1 x 10- UF-1 cells
Surface markeranalysis
Cell-surface antigens were detected by immunofluoresence
staining w-ith monoclonal antibodies including CD3. CD4. CD5.
CD7. CD8. CDIO. CD1 lb. CD13. CD14. CDl9. CD2O. HLA-DR.
CD33. CD34. CD38 and CD41 (Becton Dickinson. Mountain
Vie,w. CA. USA). The cells were analvsed bx flou- cvtometrv
(FACScan. Becton Dickinson) and the data represent the mean of
triplicate expenments.
RT-PCR assay for PML/RARa fusion transcript
RT-PCR assav for PM[IRARa was carried out u-ith both parental
UTF-I and LT-I/GMTI SCID cells. as well as control HL-60 cells
as previously descnrbed (Kizak-i et al. 1996a).
FISH analysis
To confirm the cxtogenetic findings. fluorescence in situ
hNbridization (FISH) Aas performed on slides from the same
culture as cvtogenetics u-ith specific DNA probes for RARa and
PML (Hioms et al. 1994).
Assays forcellularproliferation and differentiation
Parental UF-l and UF-I/GMTg SCID cells. as well as NB4 cells.
w-ere cultured with all-trans RA ( I0-'-l0I0- M for 4 days. Cellular
proliferation was measured using a non-radioactive cell prolifera-
tion assay system (MTT assay: Boehringer Mannheim.
Indianapolis. IN. USA) according to the manufacturer's protocol.
For analysis of cellular differentiation. cells w-ere exaniined bv
morphology usinc Giemsa staining and expression of cell-surface
CD 1 b. Cells u-ere incubated for 60 min A-ith human AB serum
(Sigma) to block Fc receptors and then stained with phycoervthrin
(PE1-conjugated mouse anti-human CD1 1b antibody (Becton
Dickinson) (Kizaki et al. 1996b).
RESULTS
Inoculation of UF-1 cells into hGMTg SCID mice
RA-resistant human APL cells (UTF-1) (I x 10-) were injected
either intraperitoneallx (i.p.) or subcutaneously (s.c.) into four
hGMTg SCID mice and four control B6J SCID mice. Endogenous
serum human GM-CSF lexels were detected in all hGMTg SCID
mice (6640-10 000 pg ml-') but not in any non-transgenic B6J
SCID mice (Table 1). IJF-1 cells formed tumours at the injected
site as subcutaneous tumours in 4 out of 4 hGMTg SCID mice
between daxs 20 and 59 (Table 1). Subcutaneous tumour. intra-
abdominal tumour and ascites w-ere developed in only one mouse
with i.p. injection (Table l). All of the tumours were composed of
leukaemic cells: howexer. no obvious infiltration Axas obserxed in
the major organs in both hGMNTg SCID and control B6J mice
(Figure lA and B. and data not shown). Only I out of 4 control
mice dexeloped a small subcutaneous tumour: this was found at
autopsy (Table l).
Morphology of UF-1/GMTg SCID cells
Singrle-cell suspensions from tumours were collected and cultured
in RPMI-1640 medium. Cells proliferated without any haemato-
poietic growth factors and were designated as UF-l/GMTc SCID
cells. JF-l/GMTg SCID cells were similar in morphologx to
parental UF-1 cells. UF-l/GMTg SCID cells and parental UF-1
Table 2 Reactvity of parental UF-1 cells and UF-1/GMTg SCID cells with monocdonal antibodies
Monoclonal antibodies (% of positive cells)
Cells CD3 CD4 CD5 CD7 CD8 CD10 CD11b CD13 CD14 CD19 CD20 HLA-DR CD33 CD34 CD38 CD41
Parental <1 <1 2 91 5 2 1 38 22 <1 <1 1 91 <1 65 1
UF-1
UF-1/GMTg 1 1 <1 85 <1 1 8 35 1 <1 1 1 8 1 44 1
SCID
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Figure 2 Karyotype of UF-1/GMTg SCID cells, showing 46. XX, add(l)(q44). add(6)(ql2), add(7)(q36) and t(15:17)(q22.qll-12)
cells showved large and often lobulated nuclei with a few- nucleoli.
and contained large azurophilic granules that were compatible with
hypergranulocvtic promyelocytes (Figure IC and D).
Surface marker analysis
Phenotypic analysis using Xarious monoclonal antibodies in
parental LFF-1 and UF-I/GMTg SCID cells is summarized in Table
2. Leukaemic cells displayed the same phenotype as parental cells.
Both types of cells were positixe for CD7. CD13 and CD38.
Interestinghl. parental UF-I cells Awere 91%'Xc positive for CD33.
whereas UF-I/G.MTg SCID cells were only 8%c positixe (Table 2).
Cytogenetic and FISH studies
C-togenetic analysis of G-tn psin-banded karvotypes was
performed on 20 metaphases. Both UF-l/GMTg SCID cells and
parental LT-I cells showed t(15:17) (q2:ql1-12) and additional
abnormalities of addUlM(q44). add(6Hq1) and add(7)(q36)
(Figure 2). To confirm the cvtogenetic studies. we performed
FHSH analvsis using metaphase chromosomes from UTF-1/GMTg
SCID cells. PMIJRARa fusion signals were detected in all
samples (Figure 3).
RT-PCR analysis of PMLJRAR-a fusion transcripts
We also examined the expression of PMIJRAR-ct chimeric
transcript in IJF-1/GMTg SCID cells by using RT-PCR. The
PML/RAR-a transcript was detected in both parental UF-1 and
LT-I/GMTg SCID cells. but not in HL-60 cells (necative control).
These results w-ere confirmed by subsequent Southern blotting of
the PCR products (Figure 4).
Effects of all-trans RA on proliferation and
differentiation of NB4, parental UF-1 and UF-1/GMTg
SCID cells
RA-sensitive NB4 cells. parental UF-l and UF-l/GMTg SCID
cells w-ere incubated w-ith all-trans RA (1'0-' to I0- m) for 4 days.
All-trans RA inhibited cellular proliferation of NB4 cells in a
dose-dependent manner (Figure 5A). By contrast. the absorbance
of MTT was changed more gradually in parental UF-1 and UF-
l/GMTga SCID cells. suggesting that all-trans RA did not affect
cell growth at 10-1'-' to I0- mI RA. However. cell proliferation
decreased by 30%7 and 40%c. respectively. after parental UF-l and
UF- 1/GMTg, SCID cells were exposed to higher concentrations of
all-trans RA (IO0- m) (Figure 5A).
Induction ofdifferentiation of these cell lines into mature gran-
ulocvtes by all-trans RA wvas assessed by morphology and expres-
sion of CD1 lb using FACS analysis (Figure 5B). NB4 cells Aere
differentiated towards mature granulocN-tes by RA. whereas all-
trans RA did not cause morphological differentiation of parental
UF-l and UTF-l/GMTg SCID cells towards either mature aranulo-
cvtes or monocvtes (data not shown). CDllb expression in NB4
cells was increased by RA in a dose-dependent manner. In
contrast. all-trans RA did not alter CD11b expression in UF-
l/GMTa SCID cells except at 10- M. These results were similar
to those obtained in parental IJF-1 cells. suggaestina that both
parental UF-1 and UF-l/GMTg SCID cells w-ere resistant to
induction ofcellular differentiation bv all-trans RA.
DISCUSSION
APL is characterized by the t( 15:17 translocation. w-hich fuses the
PML gene on chromosome 15 to the RAR-a aene on chromosome
17. and this PML/RAR-a fusion transcript may be inxolved in the
leukaemogyenesis of APL (Warrell et al. 1993). All-trans RA is
now^ being used in the treatment of APL as differentiation-
inducina therapy (Huang, et al. 1988: Warrell et al. 1991:
Kanamaru et al. 1995). Although a high proportion of patients
with APL achieve complete remission with all-trans RA. most
patients x ill develop early clinical relapse and eventual resistance
to retinoids (Warrell et al. 1993). To date. most approaches have
not been successful in oxercoming RA resistance in patients: thus.
a suitable animal model of APL is important.
SCID mice provide a model system to study the biology of
human leukaemias and explore the feasibilitv and efficacy of
noxel therapeutic approaches to leukaemia. Many studies have
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Figure 3 FISH on a representative metaphase from UF-1/GMTg SCID cells. Arrows show the PML gene (red) and the RAR-a gene (green), and the
arrowhead indicates the specific signal of the fusion gene
1 2 3
324 bp X
Figure 4 RT-PCR analysis of PMURARa fusion transcript. T
extracted from HL-60 cells (lane 1). parental UF-1 cells (lane 2
UF-1/GMTg SCID cells (lane 3). RT-PCR products were electi
transferred and hybridized with PMLJRAR-a- and (-actin-spec
The 324-bp product indicates the presence of PML/RAR-a fus
and subsequent hybridization with F-actin probe is performed
RT-PCR products in each lane
been done to establish a SCID model of human
including acute mvelocvtic leukaemia (ANIL . Hoi
plained graft failures hax-e been obsenred. and in
mveloid leukaemic cells into SCID mice has genera
successful than lymphoid leukaemic cell inoculation (Lord et al.
1991: Sawvers et al. 1992: Namikaw-a et al. 1993). Therefore.
several investigations have attempted to improve enggraftment of
human mveloid leukaemic cells in SCID mice using, various
haematopoietic grow%th factors and human fetal tissues (Terpstra et
PMLURAR-Q al. 1995). Recentlx. Lapidot et al (19941 have reported that primary
leukaemic cells injected into sublethallv irradiated SCID mice that
were treated with cvtokines (PIXY32 1 and SCF) resulted in highlx
reproducible enoraftment in mice. To resolve these problems. we
has-e established transgenic mice producing, human GM-CSF w-ith
homozvogous scid gene (hGMTg, SCID mice) (MNlivakawa et al.
1996). We have alreadx shown that functional hGM-CSF axp
fK-Acfn receptor-transfected BalF3 cells formed tumours and invaded
organs in this hGMTg, SCID model. sugaestina that these mice
w,ould be a useful model for human mveloid leukaemias. In the botal RNA was
2) and present studv. w-e created a human RA-resistant APL SCID mouse
rophoresed. model using this sx stem.
Afc probes.
C rintranscnpt. The growth pattern of subcutaneouslx inoculated human
as a control for prima m eloid leukaemic cells in SCID mice has correlated v-ith
clinical outcomes (Yan et al. 1996). APL cells have strik-incrI low-
proliferation potential in vitro: therefore. leukaemic cells from
patients with APL are more difficult to transplant into SCID mice
leukaemias. than othertypes ofmyeloid leukaemia (Cesano et al. 1992: Yan et
wever. unex- al. 1996). We haxe previouslI established and characterized a
ioculation of novel APL cell line (IUF-1) with RA-resistant features (Kizaki et
illv been less al. 1996a.) This cell line had an enhanced proliferation in the pres-
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Figure 5 Comparison of the proliferation and differentiation-inducing
actives of all-trans RA on RA-sensitive NB4 cells. RA-resistant parental
UF-1 and UF-1/GMTg SCID cells. (A) MTT assay. Cells were cultured in the
presence of all-trans RA (10-'° to 10-i M) for 4 days and MTT incorporation
was measured. Results are expressed as a per cent of control absorbance
and the mean of three experiments: the s.d. was 10% of the mean.
(B) Expression of CD11b on NB4, parental UF-1 and UF-1/SCID cells. Cells
were treated for 4 days with all-trans RA and then analysed by FACS. Data
represent the means of triplicate experiments and the s.d. was within 100o of
the mean
has been onl one APL mouse model usinc RA-sensitive NB4
cells and SCID mice (Zhang et al. 1996). NB4 cells (1 x 106 cells)
w-ere transplanted into the peritoneum of SCID mice and then
appeared as NB4 ascites cells (A-NB4). which differentiated into
mature granulocytes by all-trans RA (Zhang et al. 1996). In
contrast to A-NB4 cells. all-trans RA did not change the morpho-
logical features and CDllb expression or growth rate of UF-
l/GMTg SCID cells, indicatinc that these cells are resistant to RA.
Thus. these mice are the first human RA-resistant APL animal
model.
LT-l/GMTg SCID cells wxere positixe for CD7. CDl3 and
CD38 and necative for CD34. These results are similar to parental
LTI-l cells (Kizaki et al. 1996a). Interestingly. CD33 and CDi4
were expressed in parental lU-1 cells but not in LIE-l/GMTh SCID cells. The reason for this findin, is unclear. Because CDl4
is preferentially expressed in monocyte-like cells. a certainchange
in cell phenotype might be occurring. In addition, perhaps the
CD33-negatixe leukaemic cells had a grow-th advantage in vxVo
dungn, establishment and dexelopment ofthis APL mice model. It
has been reported that leukaemic cell proliferation and high levels
of blast colonv-formingy units (AML-CFIU) were observed in
CD34-positive cells, and CD34-negative cells were poorlI
engrafted into SCID mice (Lapidod et al. 1994). suggestinc that
expression ofCD34. but not CD33. is important for engraftment.
Consistent with this report. w-e could not reproducibly inoculate
UF-1 cells into control B6J SCID mice. In marked contrast. UF-1
cells w-ere successfullv engrafted in human GM-CSF. producing hGMTC SCID mice. We also haxe successfully transplanted a
variet- of leukaemic cell lines, including NB- (promyelocytic
leukaemia: Lanotte et al. 1991). LTT-7 (megakan-ocytic leukaemia:
Komatsu et al. 1991) and TF-1 (erx-throblastic leukaemia:
Kitamura et al. 1989). into these transgenic SCID mice (data not
showxn). In particular. LT1-7 and TF-l cells are leukaemic cell lines
that require GM-CSF and IL-3 for growth and survival. These
results suggest that this mouse system is more adaptixe tomxeloid leukaemic cells and mav be a useful in xvixo model of human
myveloid leukaemia. The leukaemic cells spreading, to the
haematopoietic tissues. includin- bone marrow- and peripheral
blood, would be an ideal model for human leukaemia. Therefore.
further studies and additional treatment ofhGMTg, SCID mice w-ill
be needed to develop an ideal animal model.
In summarx. using hGMTg, SCID mice. we established a human
RA-resistant APL mouse model. In addition to intra-abdominal
and ascites manifestations of APL. w-e successfully transplanted
LTF-I cells into hGNMTgro SCID mice as subcutaneous tumours.
Recent clinical and in xitro studies in China have shown that
arsenic trioxide is an effectixe and safe druc in the treatment
of APL patients refractory to all-trans RA (Chen et al. 1996).
However. no animal studies on arsenic trioxide exist to determine
the lethal dose and detailed pharmacokinetics in vixvo. Therefore.
this RA-resistant APL model w-ill be useful for investWiatina the
dexelopment of novel therapeutic strategies includincu arsenic
trioxide and the mechanisms of RA resistance in mveloid
leukaemia.
ence ofGM-CSF. IL-3 and SCF. but not G-CSF. M-CSF. IL-6. and
TGF- in x-itro (Kizak-i et al. 1996a). Thus. UF- l cells A ere trans-
planted into our hGNlTg SCID mice. and w-e could establish a
human APL mouse model. and single-cell suspensions (lIE-
l/GMTg, SCID cells) w-ere obtained from tumours. To date. there
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